Skip to main content
Log in

Differential Effects of Raloxifene, Tamoxifen and Fulvestrant on a Murine Mammary Carcinoma

Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The purpose of this study was to evaluate the effect of the selective estrogen receptor modulators raloxifene and tamoxifen and of the pure antiestrogen fulvestrant on tumor growth and progesterone receptor (PR) expression in an experimental model of breast cancer. The effects of these compounds on cell proliferation were studied in primary cultures of a progestin-dependent mammary carcinoma tumor line, in the presence of medroxyprogesterone acetate (MPA) or 17-β-estradiol (E2). In in vivo studies the tumor was inoculated subcutaneously in BALB/c female mice treated with 20 mg MPA depot. Raloxifene (12.5 mg/kg) or tamoxifen (5 mg/kg) were administered in daily doses or E2 silastic pellets (5 mg) were implanted. When the tumors reached about 25–50 mm2 MPA was removed in half of the animals. E2 induced complete tumor regressions, tamoxifen inhibited tumor growth in vivo while raloxifene disclosed proliferative effects in animals in which MPA had been removed. In vitro, E2 inhibited cell proliferation at concentrations higher than 10−14 M. Raloxifene and fulvestrant, but not tamoxifen, partially reverted E2-induced inhibition. Fulvestrant and tamoxifen inhibited MPA-induced cell proliferation while raloxifene had a stimulatory effect. Tamoxifen and E2 increased, raloxifene induced no effect, and fulvestrant significantly decreased PR expression. In this study we provide evidence for differential effects of tamoxifen and raloxifene on experimental mammary tumors. Since raloxifene is under evaluation for use in breast cancer prevention, these results may have important clinical implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB: The partial agonist activity of antagonistoccupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors NCoR or SMRT. Mol Endocrinol 11: 693–705, 1997

    Google Scholar 

  2. Jordan VC, Morrow M: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20: 253–278, 1999

    Google Scholar 

  3. Meyer ME, Pornon A, Ji JW, Bocquel MT, Chambon P, Gronemeyer H: Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J 9: 3923–3932, 1990

    Google Scholar 

  4. Sartorius CA, Tung L, Takimoto GS, Horwitz KB: Antagonistoccupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by camp. J Biol Chem 268: 9262–9266, 1993

    Google Scholar 

  5. Jordan VC: The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 70: 977–982, 1992

    Google Scholar 

  6. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451–1467, 1998

    Google Scholar 

  7. Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75: 305–316, 1977

    Google Scholar 

  8. Osborne CK, Hobbs K, Clark GM: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45: 584–590, 1985

    Google Scholar 

  9. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer [see comments]. New Engl J Med 326: 852–856, 1992

    Google Scholar 

  10. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32: 1031–1036, 1983

    Google Scholar 

  11. Clemens JA, Bennett DR, Black LJ, Jones CD: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 32: 2869–2875, 1983

    Google Scholar 

  12. Howell A, Downey S, Anderson E: New endocrine therapies for breast cancer. Eur J Cancer 32A: 576–588, 1996

    Google Scholar 

  13. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867–3873, 1991

    Google Scholar 

  14. Howell A: Faslodex (ICI 182780): an oestrogen receptor downregulator. Eur J Cancer 36(Suppl 4): S87–S88, 2000

    Google Scholar 

  15. Gottardis MM, Jordan VC: Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020–4024, 1987

    Google Scholar 

  16. Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res T 3 (Suppl): S73–S86, 1983

    Google Scholar 

  17. Welsch CW, Goodrich-Smith M, Brown CK, Miglorie N, Clifton KH: Effect of an estrogen antagonist (tamoxifen) on the initiation and progression of gamma-irradiation-induced mammary tumors in female Sprague-Dawley rats. Eur J Cancer Clin On 17: 1255–1258, 1981

    Google Scholar 

  18. Jordan VC, Lababidi MK, Langan-Fahey S: Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer I 83: 492–496, 1991

    Google Scholar 

  19. Jordan VC: Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 60: 1409–1419, 1976

    Google Scholar 

  20. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB: Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer I 88: 123–125, 1996

    Google Scholar 

  21. Lanari C, Molinolo AA, Pasqualini CD: Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett 33: 215–223, 1986

    Google Scholar 

  22. Molinolo AA, Lanari C, Charreau EH, Sanjuan N, Pasqualini CD: Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. J Natl Cancer I 79: 1341–1350, 1987

    Google Scholar 

  23. Kordon EC, Guerra F, Molinolo AA, Charreau EH, Pasqualini CD, Pazos P, Dran G, Lanari C: Effect of sialoadenectomy on medroxyprogesterone-acetate-induced mammary SERMs and murine mammary carcinomas 35 carcinogenesis in BALB/c mice. Correlation between histology and epidermal-growth-factor receptor content. Int J Cancer 59: 196–203, 1994

    Google Scholar 

  24. Kordon E, Lanari C, Molinolo AA, Elizalde PV, Charreau EH, Pasqualini CD: Estrogen inhibition of MPA-induced mouse mammary tumor transplants. Int J Cancer 49: 900–905, 1991

    Google Scholar 

  25. Montecchia MF, Lamb C, Molinolo AA, Luthy IA, Pazos P, Charreau E, Vanzulli S, Lanari C: Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas. J Steroid Biochem 68: 11–21, 1999

    Google Scholar 

  26. Kordon E, Lanari C, Meiss R, Charreau E, Pasqualini CD: Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res T 17: 33–43, 1990

    Google Scholar 

  27. Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo AA: Five novel hormoneresponsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61: 293–302, 2001

    Google Scholar 

  28. Dran G, Luthy IA, Molinolo AA, Charreau EH, Pasqualini CD, Lanari C: Effect of medroxyprogesterone acetate (MPA) and serum factors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma. Breast Cancer Res T 35: 173–186, 1995

    Google Scholar 

  29. Lowry OH, Rosebrough NJ, Farr AL: Protein measurements with the Folin phenol reagent. J Biol Chem 193: 265–275, 1951

    Google Scholar 

  30. Clarke R, Leonessa F, Welch JN, Skaar TC: Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53: 25–71, 2001

    Google Scholar 

  31. Going JJ, Anderson TJ, Battersby S, MacIntyre CC: Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130: 193–204, 1988

    Google Scholar 

  32. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C: The risk of breast cancer after estrogen and estrogen-progestin replacement. New Engl J Med 321: 293–297, 1989

    Google Scholar 

  33. Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer I 92: 328–332, 2000

    Google Scholar 

  34. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL: Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res T 54: 117–122, 1999

    Google Scholar 

  35. Brunner N, Spang-Thomsen M, Cullen K: The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res T 39: 87–92, 1996

    Google Scholar 

  36. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA: Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 7: 3156–3165, 2001

    Google Scholar 

  37. Powell CE, Soto AM, Sonnenschein C: Identification and characterization of membrane estrogen receptor from MCF7 estrogen-target cells. J Steroid Biochem 77: 97–108, 2001

    Google Scholar 

  38. Masamura S, Santner SJ, Heitjan DF, Santen RJ: Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocr Metab 80: 2918–2925, 1995

    Google Scholar 

  39. Chun TY, Gregg D, Sarkar DK, Gorski J: Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth. P Natl Acad Sci USA 950: 2325–2330, 1998

    Google Scholar 

  40. Endoh H, Sasaki H, Maruyama K, Takeyama K, Waga I, Shimizu T, Kato S, Kawashima H: Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem Bioph Res Co 235: 99–102, 1997

    Google Scholar 

  41. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, Redinbo MR: The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292: 2329–2333, 2001

    Google Scholar 

  42. Weatherman RV, Fletterick RJ, Scanlan TS: Nuclear-receptor ligands and ligand-binding domains. Annu Rev Biochem 68: 559–581, 1999

    Google Scholar 

  43. Benten WP, Stephan C, Lieberherr M, Wunderlich F: Estradiol signaling via sequestrable surface receptors. Endocrinology 42: 1669–1677, 2001

    Google Scholar 

  44. Horwitz KB, Koseki Y, McGuire WL: Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103: 1742–1751, 1978

    Google Scholar 

  45. Lamb C, Simian M, Molinolo A, Pazos P, Lanari C: Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation. J Steroid Biochem 70: 133–142, 1999

    Google Scholar 

  46. Nawaz Z, Stancel GM, Hyder SM: The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. Cancer Res 59: 372–376, 1999

    Google Scholar 

  47. Watson C, Medina D, Clark JH: Estrogen receptor characterization in a transplantable mouse mammary tumor. Cancer Res 37: 3344–3348, 1977

    Google Scholar 

  48. Wakeling AE, Bowler J: Steroidal pure antioestrogens. J Endocrinol 112: R7–10, 1987

    Google Scholar 

  49. Kaye AM, Spatz M, Waisman A, Sasson S, Tamir S, Vaya J, Somjen D: Paradoxical interactions among estrogen receptors, estrogens and SERMS: mutual annihilation and synergy. J Steroid Biochem 76: 85–93, 2001

    Google Scholar 

  50. Kordon EC, Molinolo AA, Pasqualini CD, Charreau EH, Pazos P, Dran G, Lanari C: Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between progestin dependence and morphology. Breast Cancer Res T 28: 29–39, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lamb, C.A., Helguero, L.A., Fabris, V. et al. Differential Effects of Raloxifene, Tamoxifen and Fulvestrant on a Murine Mammary Carcinoma. Breast Cancer Res Treat 79, 25–35 (2003). https://doi.org/10.1023/A:1023324827225

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023324827225

Navigation